Articles

Two heads are better than one

LGC’s Genomics division combines with KBioscience with aim of creating a market leading genomics position
Written byJeffrey Bouley
| 3 min read

TEDDINGTON, U.K.—Looking to create "a market-leading genomicservices and solutions provider," LGC Ltd., global company focused onanalytical, diagnostic and forensic services and reference standards, acquired KBioscienceLtd. at the beginning of July.

According to LGC, the acquisition of KBioscience, "with itsunique expertise in genotyping services, chemistries and related products,"extends and complements the genomic services and products supplied through LGC'sGenomics Division.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.